1
|
Vadevoo SMP, Gurung S, Lee HS, Gunassekaran GR, Lee SM, Yoon JW, Lee YK, Lee B. Peptides as multifunctional players in cancer therapy. Exp Mol Med 2023; 55:1099-1109. [PMID: 37258584 PMCID: PMC10318096 DOI: 10.1038/s12276-023-01016-x] [Citation(s) in RCA: 23] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2023] [Revised: 03/21/2023] [Accepted: 03/24/2023] [Indexed: 06/02/2023] Open
Abstract
Peptides exhibit lower affinity and a shorter half-life in the body than antibodies. Conversely, peptides demonstrate higher efficiency in tissue penetration and cell internalization than antibodies. Regardless of the pros and cons of peptides, they have been used as tumor-homing ligands for delivering carriers (such as nanoparticles, extracellular vesicles, and cells) and cargoes (such as cytotoxic peptides and radioisotopes) to tumors. Additionally, tumor-homing peptides have been conjugated with cargoes such as small-molecule or chemotherapeutic drugs via linkers to synthesize peptide-drug conjugates. In addition, peptides selectively bind to cell surface receptors and proteins, such as immune checkpoints, receptor kinases, and hormone receptors, subsequently blocking their biological activity or serving as hormone analogs. Furthermore, peptides internalized into cells bind to intracellular proteins and interfere with protein-protein interactions. Thus, peptides demonstrate great application potential as multifunctional players in cancer therapy.
Collapse
Affiliation(s)
- Sri Murugan Poongkavithai Vadevoo
- Department of Biochemistry and Cell Biology, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
- Department of Biomedical Science, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
- Cell & Matrix Research Institute, School of Medicine, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
| | - Smriti Gurung
- Department of Biochemistry and Cell Biology, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
- Department of Biomedical Science, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
- Cell & Matrix Research Institute, School of Medicine, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
| | - Hyun-Su Lee
- Department of Physiology, Daegu Catholic University School of Medicine, 33 Duryugongwon-ro 17-gil, Nam-gu, Daegu, 42472, Republic of Korea
| | - Gowri Rangaswamy Gunassekaran
- Department of Biochemistry and Cell Biology, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
- Department of Biomedical Science, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
- Cell & Matrix Research Institute, School of Medicine, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
| | - Seok-Min Lee
- Department of Biochemistry and Cell Biology, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
- Department of Biomedical Science, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
- Cell & Matrix Research Institute, School of Medicine, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
| | - Jae-Won Yoon
- Department of Biochemistry and Cell Biology, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
- Department of Biomedical Science, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
- Cell & Matrix Research Institute, School of Medicine, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
| | - Yun-Ki Lee
- Department of Biochemistry and Cell Biology, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
- Department of Biomedical Science, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
- Cell & Matrix Research Institute, School of Medicine, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea
| | - Byungheon Lee
- Department of Biochemistry and Cell Biology, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea.
- Department of Biomedical Science, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea.
- Cell & Matrix Research Institute, School of Medicine, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea.
| |
Collapse
|
2
|
Yang Y, Luo R, Chao S, Xue J, Jiang D, Feng YH, Guo XD, Luo D, Zhang J, Li Z, Wang ZL. Improved pharmacodynamics of epidermal growth factor via microneedles-based self-powered transcutaneous electrical stimulation. Nat Commun 2022; 13:6908. [PMID: 36376334 PMCID: PMC9663450 DOI: 10.1038/s41467-022-34716-5] [Citation(s) in RCA: 34] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Accepted: 11/03/2022] [Indexed: 11/16/2022] Open
Abstract
Epidermal growth factor is an excellent drug for promoting wound healing; however, its conventional administration strategies are associated with pharmacodynamic challenges, such as low transdermal permeability, reduction, and receptor desensitization. Here, we develop a microneedle-based self-powered transcutaneous electrical stimulation system (mn-STESS) by integrating a sliding free-standing triboelectric nanogenerator with a microneedle patch to achieve improved epidermal growth factor pharmacodynamics. We show that the mn-STESS facilitates drug penetration and utilization by using microneedles to pierce the stratum corneum. More importantly, we find that it converts the mechanical energy of finger sliding into electricity and mediates transcutaneous electrical stimulation through microneedles. We demonstrate that the electrical stimulation applied by mn-STESS acts as an "adjuvant" that suppresses the reduction of epidermal growth factor by glutathione and upregulates its receptor expression in keratinocyte cells, successfully compensating for receptor desensitization. Collectively, this work highlights the promise of self-powered electrical adjuvants in improving drug pharmacodynamics, creating combinatorial therapeutic strategies for traditional drugs.
Collapse
Affiliation(s)
- Yuan Yang
- Beijing Institute of Nanoenergy and Nanosystems, Chinese Academy of Sciences, Beijing, 101400, China
- Department of Plastic Surgery, State Key Laboratory of Trauma, Burns and Combined Injury, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, 400038, China
- School of Nanoscience and Technology, University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Ruizeng Luo
- Beijing Institute of Nanoenergy and Nanosystems, Chinese Academy of Sciences, Beijing, 101400, China
- School of Nanoscience and Technology, University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Shengyu Chao
- Beijing Institute of Nanoenergy and Nanosystems, Chinese Academy of Sciences, Beijing, 101400, China
- School of Nanoscience and Technology, University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Jiangtao Xue
- Institute of Engineering Medicine, Beijing Institute of Technology, Beijing, 100081, China
| | - Dongjie Jiang
- Beijing Institute of Nanoenergy and Nanosystems, Chinese Academy of Sciences, Beijing, 101400, China
- School of Nanoscience and Technology, University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Yun Hao Feng
- Beijing Laboratory of Biomedical Materials, College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing, 100029, China
| | - Xin Dong Guo
- Beijing Laboratory of Biomedical Materials, College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing, 100029, China
| | - Dan Luo
- Beijing Institute of Nanoenergy and Nanosystems, Chinese Academy of Sciences, Beijing, 101400, China.
- School of Nanoscience and Technology, University of Chinese Academy of Sciences, Beijing, 100049, China.
- Center of Nanoenergy Research, School of Physical Science and Technology, Guangxi University, Nanning, 530004, China.
| | - Jiaping Zhang
- Department of Plastic Surgery, State Key Laboratory of Trauma, Burns and Combined Injury, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, 400038, China.
| | - Zhou Li
- Beijing Institute of Nanoenergy and Nanosystems, Chinese Academy of Sciences, Beijing, 101400, China.
- School of Nanoscience and Technology, University of Chinese Academy of Sciences, Beijing, 100049, China.
- Center of Nanoenergy Research, School of Physical Science and Technology, Guangxi University, Nanning, 530004, China.
- Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, 100101, China.
| | - Zhong Lin Wang
- Beijing Institute of Nanoenergy and Nanosystems, Chinese Academy of Sciences, Beijing, 101400, China
- Georgia Institute of Technology, Atlanta, GA, 30332 0245, USA
| |
Collapse
|
3
|
Challenges for the application of EGFR-targeting peptide GE11 in tumor diagnosis and treatment. J Control Release 2022; 349:592-605. [PMID: 35872181 DOI: 10.1016/j.jconrel.2022.07.018] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Revised: 07/15/2022] [Accepted: 07/16/2022] [Indexed: 11/20/2022]
Abstract
Abnormal regulation of cell signaling pathways on cell survival, proliferation and migration contributes to the development of malignant tumors. Among them, epidermal growth factor receptor (EGFR) is one of the most important biomarkers in many types of malignant solid tumors. Its over-expression and mutation status can be served as a biomarker to identify patients who can be benifit from EGFR tyrosine kinase inhibitors and anti-EGFR monocloncal antibody (mAb) therapy. For decades, researches on EGFR targeted ligands were actively carried out to identify potent candidates for cancer therapy. An ideal EGFR ligand can competitively inhibit the binding of endogenous growth factor, such as epidermal growth factor (EGF) and transforming growth factor-α(TGF-α) to EGFR, thus block EGFR signaling pathway and downregulate EGFR expression. Alternatively, conjugation of EGFR ligands on drug delivery systems (DDS) can facilitate targeting delivery of therapeutics or diagnostic agents to EGFR over-expression tumors via EGFR-mediated endocytosis. GE11 peptide is one of the potent EGFR ligand screened from a phage display peptide library. It is a dodecapeptide that can specifically binds to EGFR with high affinity and selectivity. GE11 has been widely used in the diagnosis and targeted delivery of drugs for radiotherapy, genetherapy and chemotherpy against EGFR positive tumors. In this review, the critical factors affecting the in vivo and in vitro targeting performance of GE11 peptide, including ligand-receptor intermolecular force, linker bond properties and physiochemical properties of carrier materials, are detailedly interpreted. This review provides a valuable vision for the rational design and optimization of GE11-based active targeting strategies for cancer treatment, and it will promote the translation studies of GE11 from lab research to clinical application.
Collapse
|
4
|
Xiao C, Han J, Bai J, Xia Y, Wang S. Trojan-Like Peptide Drug Conjugate Design and Construction for Application in Treatment of Triple-Negative Breast Cancer. J Biomed Nanotechnol 2021; 17:1554-1563. [PMID: 34544533 DOI: 10.1166/jbn.2021.3104] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Clinical treatment of triple negative breast cancer (TNBC) is very poor for lack of effective treatment combination selection. Protein C receptor (PROCR) is a novel cancer stem marker in TNBC patients tumor tissues. Developed based on peptide BP10 with affinity to PROCR as a targeting element, constructing a peptide drug conjugate of BP10 covalently coupling doxorubicin with disulfide bonds. This study demonstrated that the constructed BP10-DOX can selectively target Triplenegative breast cancer cells expressing PROCR and controlled release of DOX in response to the GSH environment. Moreover, BP10-DOX improves the therapeutic efficiency on MDA-MB-231 cells in vitro. Further evidence obtained from in vivo xenograft experiments revealed that administration of BP10-DOX enhanced the antitumor efficacy. This study developed a promising chemotherapy strategy for TNBC.
Collapse
Affiliation(s)
- Chuanguang Xiao
- Department of Breast and Thyroid Surgery, Zibo Central Hospital, Zibo, Shandong, 255036, P. R. China
| | - Jieru Han
- Departments of the Golden Chamber, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150040, P. R. China
| | - Jixiang Bai
- Department of Urinary Surgery, Mudanjiang Medical University Affiliated Hongqi Hospital, Mudanjiang, Heilongjiang Province, 157000, P. R. China
| | - Yanjie Xia
- Department of Laboratory, Mudanjiang Medical University Affiliated Hongqi Hospital, Mudanjiang, Heilongjiang Province, 157000, P. R. China
| | - Shuhui Wang
- Department of Integrative Medicine & Geratology, Mudanjiang Medical University Affiliated Hongqi Hospital, Mudanjiang, Heilongjiang Province, 157000, P. R. China
| |
Collapse
|
5
|
Fan M, Li J. A Novel Combinational Nanodrug Delivery System Induces Synergistic Inhibition of Lung Adenocarcinoma Cells In vitro. LETT DRUG DES DISCOV 2021. [DOI: 10.2174/1570180817999200719152426] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
The combination of two or more therapeutic drugs is an attractive approach
to improve the treatment of experimental tumors. Leveraging nanocarriers for combinational drug
delivery can allow control over drug biological fate and promote co-localization in the same area of
the body. However, there are certain concerns regarding the biodegradability and potential longterm
toxicity arising from these synthetic nanoscale carriers.
Objective:
Our aim was to develop a combinational nanodrug delivery system formed by selfassembling
of amphiphilic drug molecules.minimizing potential toxicities associated with using
additional synthetic nanocarriers.
Methods:
A novel prodrug chlorambucil gemcitabine conjugate was synthesized, this prodrug was
used for the encapsulation of an additional hydrophobic anticancer drug paclitaxel, taking the form
of combinational nanodrugs. Particle size and zeta potential were evaluated, cytotoxicity assay and
apoptosis/cell cycle analysis were also performed to validate the anticancer efficacy of the combinational
nanodrugs.
Results:
The combinational nanodrugs were acquired by means of nanoprecipitation. In A549 lung
adenocarcinoma cell line, cellular assays revealed that co-delivery of low dosage paclitaxel with
chlorambucil gemcitabine conjugate can act synergistically to inhibit cell growth and induce accumulation
of cells in the G2/M phase with a concomitant decrease in G0/G1 compartment.
Conclusion:
Chlorambucil gemcitabine conjugate and paclitaxel can co-assemble into composite
nanoparticles by a nanoprecipitation process and the resulting combinational nanodrugs showed a
synergistic anticancer effect. This synthetic nanocarrier-free approach might broaden the nanodrug
concept and have potential in cancer therapy.
Collapse
Affiliation(s)
- Mingliang Fan
- School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China
| | - Jiping Li
- Department of Otolaryngology, Renji Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, 200032, China
| |
Collapse
|
6
|
Chen L, Chen G, Yang Z, Wang H, Liu N, Liu Y, Fang K, Song Y, Guan X. Enhanced cancer treatment by an acid-sensitive cytotoxic peptide-doxorubicin conjugate. J Drug Deliv Sci Technol 2020. [DOI: 10.1016/j.jddst.2020.102048] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
7
|
Lin ZL, Ding J, Sun GP, Li D, He SS, Liang XF, Huang XR, Xie J. Application of Paclitaxel-loaded EGFR Peptide-conjugated Magnetic Polymeric Liposomes for Liver Cancer Therapy. Curr Med Sci 2020; 40:145-154. [PMID: 32166677 DOI: 10.1007/s11596-020-2158-4] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2019] [Revised: 11/26/2019] [Indexed: 12/12/2022]
Abstract
Developing the methodologies that allow for safe and effective delivery of therapeutic drugs to target sites is a very important research area in cancer therapy. In this study, polyethylene glycol (PEG)-coated magnetic polymeric liposome (MPL) nanoparticles (NPs) assembled from octadecyl quaternized carboxymethyl chitosan (OQC), PEGylated OQC, cholesterol, and magnetic NPs, and functionalized with epithelial growth factor receptor (EGFR) peptide, were successfully prepared for in-vivo liver targeting. The two-step liver targeting strategy, based on both magnetic force and EGFR peptide conjugation, was evaluated in a subcutaneous hepatocellular carcinoma model of nude mouse. The results showed that EGFR-conjugated MPLs not only accumulated in the liver by magnetic force, but could also diffuse into tumor cells as a result of EGFR targeting. In addition, paclitaxel (PTX) was incorporated into small EGFR-conjugated MPLs (102.0±0.7 nm), resulting in spherical particles with high drug encapsulation efficiency (>90%). The use of the magnetic targeting for enhancing the transport of PTX-loaded EGFR-conjugated MPLs to the tumor site was further confirmed by detecting PTX levels. In conclusion, PTX-loaded EGFR-conjugated MPLs could potentially be used as an effective drug delivery system for targeted liver cancer therapy.
Collapse
Affiliation(s)
- Zhen-Lv Lin
- Department of Emergency, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China
| | - Jian Ding
- Department of Gastroenterology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China.
| | - Guo-Ping Sun
- Department of Pharmacy, Qingdao Seventh People's Hospital, Qingdao, 266034, China
| | - Dan Li
- Department of Gastroenterology, Union Hospital of Fujian Medical University, Fuzhou, 350001, China.
| | - Shan-Shan He
- Department of Gastroenterology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China
| | - Xiao-Fei Liang
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiaotong University School of Medicine, Shanghai, 200032, China
| | - Xun-Ru Huang
- Department of Gastroenterology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China
| | - Jie Xie
- Department of Emergency, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China.,Department of Gastroenterology, Hospital of Fujian Normal University, Fujian Normal University, Fuzhou, 350007, China
| |
Collapse
|
8
|
Ziaei E, Saghaeidehkordi A, Dill C, Maslennikov I, Chen S, Kaur K. Targeting Triple Negative Breast Cancer Cells with Novel Cytotoxic Peptide-Doxorubicin Conjugates. Bioconjug Chem 2019; 30:3098-3106. [PMID: 31715102 DOI: 10.1021/acs.bioconjchem.9b00755] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
In this study, we have designed and synthesized two novel peptide-drug conjugates (PDCs) where the drug, doxorubicin (Dox), is linked to the peptide via a succinimidyl thioether bond or a hydrazone linker. A highly specific and proteolytically stable breast cancer cell targeting peptide (WxEAAYQrFL) is conjugated to Dox to synthesize peptide-Dox thioether (1) or hydrazone (2) conjugate. The evaluation of the stability in water, media, and human serum showed that the conjugate 1 with the succinimidyl thioether linkage is more stable compared to the acid-sensitive hydrazone containing conjugate 2. The cytotoxicity studies showed that the two PDCs were as toxic as free Dox toward the triple negative breast cancer (TNBC) cells and were 7-30 times less toxic (IC50 1.2-4.7 μM for TNBC cells versus 15-39 μM for noncancerous cells) toward the noncancerous breast cells compared to the free doxorubicin (IC50 0.35-1.5 μM for TNBC cells versus 0.24 μM for noncancerous cells). The results from the comparative study of the two PDCs suggest that both may have translational potential for TNBC treatment.
Collapse
Affiliation(s)
- Elmira Ziaei
- Chapman University School of Pharmacy (CUSP), Harry and Diane Rinker Health Science Campus , Chapman University , Irvine , California 92618-1908 , United States
| | - Azam Saghaeidehkordi
- Chapman University School of Pharmacy (CUSP), Harry and Diane Rinker Health Science Campus , Chapman University , Irvine , California 92618-1908 , United States
| | - Cassandra Dill
- Chapman University School of Pharmacy (CUSP), Harry and Diane Rinker Health Science Campus , Chapman University , Irvine , California 92618-1908 , United States
| | - Innokentiy Maslennikov
- Chapman University School of Pharmacy (CUSP), Harry and Diane Rinker Health Science Campus , Chapman University , Irvine , California 92618-1908 , United States
| | - Shiuan Chen
- Department of Cancer Biology , Beckman Research Institute of the City of Hope , Duarte , California 91010 , United States
| | - Kamaljit Kaur
- Chapman University School of Pharmacy (CUSP), Harry and Diane Rinker Health Science Campus , Chapman University , Irvine , California 92618-1908 , United States
| |
Collapse
|
9
|
Transferrin Receptor Targeted Cellular Delivery of Doxorubicin Via a Reduction-Responsive Peptide-Drug Conjugate. Pharm Res 2019; 36:168. [DOI: 10.1007/s11095-019-2688-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2019] [Accepted: 08/15/2019] [Indexed: 12/11/2022]
|
10
|
Li S, Zhao H, Fan Y, Zhao G, Wang R, Wen F, Wang J, Wang X, Wang Y, Gao Y. Design, synthesis, and in vitro antitumor activity of a transferrin receptor-targeted peptide-doxorubicin conjugate. Chem Biol Drug Des 2019; 95:58-65. [PMID: 31452330 DOI: 10.1111/cbdd.13613] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Revised: 06/20/2019] [Accepted: 08/03/2019] [Indexed: 12/21/2022]
Abstract
In this study, a peptide-drug conjugate was designed and synthesized by connecting a transferrin receptor (TfR)-targeted binding peptide analog BP9a (CAHLHNRS) with doxorubicin (DOX) through N-succinimidyl-3-maleimidopropionate (SMP) as the cross-linker. Confocal laser scanning microscopy results indicated that free DOX mainly accumulated in the nuclei of both TfR overexpressed HepG2 hepatoma cells and L-O2 normal liver cells expressing low level of TfR; most of the BP9a-DOX conjugate displayed cytoplasmic location, and its cellular uptake by HepG2 cells was obviously reduced by TfR blockage test. Nevertheless, the cellular uptake of this conjugate by L-O2 cells was much less than that of free DOX. Meanwhile, the BP9a-DOX conjugate exhibited lower in vitro antiproliferative activity against HepG2 cells than free DOX, but its cytotoxic effect on L-O2 cells was decreased compared with that of free DOX. These results suggest that BP9a could be applied as a potential TfR-targeted peptide vector for selective drug delivery.
Collapse
Affiliation(s)
- Songtao Li
- Hebei Province Key Laboratory of Research and Development of Traditional Chinese Medicine, Institute of Chinese Mateia Medica, Chengde Medical University, Chengde, China
| | - Hongling Zhao
- Hebei Province Key Laboratory of Research and Development of Traditional Chinese Medicine, Institute of Chinese Mateia Medica, Chengde Medical University, Chengde, China
| | - Yanfang Fan
- Institute of Basic Medicine, Chengde Medical University, Chengde, China
| | - Guiqin Zhao
- Hebei Province Key Laboratory of Research and Development of Traditional Chinese Medicine, Institute of Chinese Mateia Medica, Chengde Medical University, Chengde, China
| | - Ruxing Wang
- Hebei Province Key Laboratory of Research and Development of Traditional Chinese Medicine, Institute of Chinese Mateia Medica, Chengde Medical University, Chengde, China
| | - Fuyu Wen
- Hebei Province Key Laboratory of Research and Development of Traditional Chinese Medicine, Institute of Chinese Mateia Medica, Chengde Medical University, Chengde, China
| | - Jianping Wang
- Department of Immunology, Chengde Medical University, Chengde, China
| | - Xiaohui Wang
- Institute of Basic Medicine, Chengde Medical University, Chengde, China
| | - Yu Wang
- Department of Traumatic Orthopaedics, Affiliated Hospital of Chengde Medical University, Chengde, China
| | - Yang Gao
- Hebei Province Key Laboratory of Research and Development of Traditional Chinese Medicine, Institute of Chinese Mateia Medica, Chengde Medical University, Chengde, China
| |
Collapse
|
11
|
Mazzuca C, Di Napoli B, Biscaglia F, Ripani G, Rajendran S, Braga A, Benna C, Mocellin S, Gobbo M, Meneghetti M, Palleschi A. Understanding the good and poor cell targeting activity of gold nanostructures functionalized with molecular units for the epidermal growth factor receptor. NANOSCALE ADVANCES 2019; 1:1970-1979. [PMID: 36134223 PMCID: PMC9417547 DOI: 10.1039/c9na00096h] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/17/2019] [Accepted: 03/29/2019] [Indexed: 05/21/2023]
Abstract
Nanostructures can strongly interact with cells or other biological structures; furthermore when they are functionalized with targeting units, they are of great interest for a variety of applications in the biotechnology field like those for efficient imaging, diagnosis and therapy and in particular for cancer theranostics. Obtaining targeting with good specificity and sensitivity is a key necessity, which, however, is affected by the complexity of the interactions between the nanostructures and the biological components. In this work we report the study of specificity and sensitivity of gold nanoparticles functionalized with the peptide GE11 for the targeting of the epidermal growth factor receptor, expressed on many cells and, in particular, on many types of cancer cells. We show how a combination of spectroscopic measurements and molecular dynamics simulations allows the comprehension of the targeting activity of peptides linked to the surface of gold nanostructures and how the targeting is tuned by the presence of polyethylene glycol chains.
Collapse
Affiliation(s)
- Claudia Mazzuca
- Department of Chemical Science and Technology, University of Rome "Tor Vergata" and CSGI Unit Via della Ricerca Scientifica 00133 Rome Italy
| | - Benedetta Di Napoli
- Department of Chemical Science and Technology, University of Rome "Tor Vergata" and CSGI Unit Via della Ricerca Scientifica 00133 Rome Italy
| | - Francesca Biscaglia
- Department of Chemical Sciences, University of Padova Via Marzolo 1 35131 Padova Italy
| | - Giorgio Ripani
- Department of Chemical Science and Technology, University of Rome "Tor Vergata" and CSGI Unit Via della Ricerca Scientifica 00133 Rome Italy
| | - Senthilkumar Rajendran
- Department of Surgery, Oncology and Gastroenterology, University of Padova Via Giustiniani, 2 35124 Padova Italy
| | - Andrea Braga
- Department of Chemical Sciences, University of Padova Via Marzolo 1 35131 Padova Italy
| | - Clara Benna
- Department of Surgery, Oncology and Gastroenterology, University of Padova Via Giustiniani, 2 35124 Padova Italy
| | - Simone Mocellin
- Department of Surgery, Oncology and Gastroenterology, University of Padova Via Giustiniani, 2 35124 Padova Italy
- Veneto Institute of Oncology IOV-IRCCS Via Gattamelata, 64 35128 Padova Italy
| | - Marina Gobbo
- Department of Chemical Sciences, University of Padova Via Marzolo 1 35131 Padova Italy
| | - Moreno Meneghetti
- Department of Chemical Sciences, University of Padova Via Marzolo 1 35131 Padova Italy
| | - Antonio Palleschi
- Department of Chemical Science and Technology, University of Rome "Tor Vergata" and CSGI Unit Via della Ricerca Scientifica 00133 Rome Italy
| |
Collapse
|
12
|
Hossein-Nejad-Ariani H, Althagafi E, Kaur K. Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells. Sci Rep 2019; 9:2723. [PMID: 30804365 PMCID: PMC6389950 DOI: 10.1038/s41598-019-38574-y] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Accepted: 12/28/2018] [Indexed: 11/09/2022] Open
Abstract
The efficacy of chemotherapy for cancer treatment can be increased by targeted drug delivery to the cancer cells. This is particularly important for triple negative breast cancer (TNBC) for which chemotherapy is a major form of treatment. Here we designed and screened a library of 30 peptides starting with a previously reported epidermal growth factor receptor (EGFR) targeting peptide GE11 (YHWYGYTPQNVI). A direct peptide array-whole cell binding assay, where the peptides are conjugated to a cellulose membrane, was used to identify four peptides with enhanced binding to TNBC cells. Next, the four peptides were synthesized as FITC-labelled soluble peptides to study their direct uptake by TNBC cells using flow cytometry. The results showed that peptide analogue 22 had several fold higher uptake by the TNBC cells compared to the lead peptide GE11. The specific uptake of the peptide analogue 22 was confirmed by competition experiment using pure EGF protein. Further, peptide 22 showed dose dependent uptake by the TNBC MDA-MB-231 cells (105) with uptake saturating at around 2 μM peptide concentration. Thus, peptide 22 is a promising EGFR specific TNBC cell binding peptide that can be conjugated directly to a chemotherapeutic drug or to nanoparticles for targeted drug delivery to enhance the efficacy of chemotherapy for TNBC treatment.
Collapse
Affiliation(s)
- Hanieh Hossein-Nejad-Ariani
- Chapman University School of Pharmacy (CUSP), Harry and Diane Rinker Health Science Campus, Chapman University, Irvine, California, 92618-1908, USA
| | - Emad Althagafi
- Chapman University School of Pharmacy (CUSP), Harry and Diane Rinker Health Science Campus, Chapman University, Irvine, California, 92618-1908, USA
| | - Kamaljit Kaur
- Chapman University School of Pharmacy (CUSP), Harry and Diane Rinker Health Science Campus, Chapman University, Irvine, California, 92618-1908, USA.
| |
Collapse
|
13
|
Abstract
There is a growing interest for the discovery of new cancer-targeted delivery systems for drug delivery and diagnosis. A synopsis of the bibliographic data will be presented on bombesin, neurotensin, octreotide, Arg-Gly-Asp, luteinizing hormone-releasing hormone and other peptides. Many of them have reached the clinics for therapeutic or diagnostic purposes, and have been utilized as carriers of known cytotoxic agents such as doxorubicin, paclitaxel, cisplatin, methotrexate or dyes and radioisotopes. In our article, recent advances in the development of peptides as carriers of cytotoxic drugs or radiometals will be analyzed.
Collapse
|
14
|
Redox-responsive microbeads containing thiolated pectin-doxorubicin conjugate inhibit tumor growth and metastasis: An in vitro and in vivo study. Int J Pharm 2018; 545:1-9. [DOI: 10.1016/j.ijpharm.2018.04.052] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Revised: 04/22/2018] [Accepted: 04/23/2018] [Indexed: 12/23/2022]
|
15
|
Shire Z, Vakili MR, Morgan TDR, Hall DG, Lavasanifar A, Weinfeld M. Nanoencapsulation of Novel Inhibitors of PNKP for Selective Sensitization to Ionizing Radiation and Irinotecan and Induction of Synthetic Lethality. Mol Pharm 2018; 15:2316-2326. [PMID: 29688721 DOI: 10.1021/acs.molpharmaceut.8b00169] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
There is increasing interest in developing and applying DNA repair inhibitors in cancer treatment to augment the efficacy of radiation and conventional genotoxic chemotherapy. However, targeting the inhibitor is required to avoid reducing the repair capacity of normal tissue. The aim of this study was to develop nanodelivery systems for the encapsulation of novel imidopiperidine-based inhibitors of the DNA 3'-phosphatase activity of polynucleotide kinase/phosphatase (PNKP), a DNA repair enzyme that plays a critical role in rejoining DNA single- and double-strand breaks. For this purpose, newly identified hit compounds with potent PNKP inhibitory activity, imidopiperidines A12B4C50 and A83B4C63 were encapsulated in polymeric micelles of different poly(ethylene oxide)- b-poly(ε-caprolactone) (PEO- b-PCL)-based structures. Our results showed efficient loading of A12B4C50 and A83B4C63 in PEO- b-PCLs with pendent carboxyl and benzyl carboxylate groups, respectively, and relatively slow release over 24 h. Both free and encapsulated inhibitors were able to sensitize HCT116 cells to radiation and the topoisomerase I poison, irinotecan. In addition, the encapsulated inhibitors were capable of inducing synthetic lethalilty in phosphatase and tensin homologue (PTEN)-deficient cells. We also established the validity of the peptide GE11 as a suitable ligand for active targeted delivery of nanoencapsulated drugs to colorectal cancer cells overexpressing epidermal growth factor receptor (EGFR). Our results show the potential of nanoencapsulated inhibitors of PNKP as either mono or combined therapeutic agents for colorectal cancer.
Collapse
Affiliation(s)
- Zahra Shire
- Department of Oncology, Faculty of Medicine and Dentistry , University of Alberta , Edmonton , AB , Canada T6G 1Z2.,Faculty of Pharmacy and Pharmaceutical Sciences , University of Alberta , Edmonton , AB , Canada T6G 2E1
| | - Mohammad Reza Vakili
- Faculty of Pharmacy and Pharmaceutical Sciences , University of Alberta , Edmonton , AB , Canada T6G 2E1
| | - Timothy D R Morgan
- Department of Chemistry, Faculty of Science , University of Alberta , Edmonton , AB , Canada T6G 2G2
| | - Dennis G Hall
- Department of Chemistry, Faculty of Science , University of Alberta , Edmonton , AB , Canada T6G 2G2
| | - Afsaneh Lavasanifar
- Faculty of Pharmacy and Pharmaceutical Sciences , University of Alberta , Edmonton , AB , Canada T6G 2E1
| | - Michael Weinfeld
- Department of Oncology, Faculty of Medicine and Dentistry , University of Alberta , Edmonton , AB , Canada T6G 1Z2
| |
Collapse
|
16
|
Genta I, Chiesa E, Colzani B, Modena T, Conti B, Dorati R. GE11 Peptide as an Active Targeting Agent in Antitumor Therapy: A Minireview. Pharmaceutics 2017; 10:E2. [PMID: 29271876 PMCID: PMC5874815 DOI: 10.3390/pharmaceutics10010002] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2017] [Revised: 12/06/2017] [Accepted: 12/11/2017] [Indexed: 01/06/2023] Open
Abstract
A lot of solid tumors are characterized by uncontrolled signal transduction triggered by receptors related to cellular growth. The targeting of these cell receptors with antitumor drugs is essential to improve chemotherapy efficacy. This can be achieved by conjugation of an active targeting agent to the polymer portion of a colloidal drug delivery system loaded with an antitumor drug. The goal of this minireview is to report and discuss some recent results in epidermal growth factor receptor targeting by the GE11 peptide combined with colloidal drug delivery systems as smart carriers for antitumor drugs. The minireview chapters will focus on explaining and discussing: (i) Epidermal growth factor receptor (EGFR) structures and functions; (ii) GE11 structure and biologic activity; (iii) examples of GE11 conjugation and GE11-conjugated drug delivery systems. The rationale is to contribute in gathering information on the topic of active targeting to tumors. A case study is introduced, involving research on tumor cell targeting by the GE11 peptide combined with polymer nanoparticles.
Collapse
Affiliation(s)
- Ida Genta
- Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.
| | - Enrica Chiesa
- Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.
| | - Barbara Colzani
- Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.
| | - Tiziana Modena
- Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.
| | - Bice Conti
- Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.
| | - Rossella Dorati
- Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.
| |
Collapse
|
17
|
Fang Y, Yang W, Cheng L, Meng F, Zhang J, Zhong Z. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo. Acta Biomater 2017; 64:323-333. [PMID: 29030307 DOI: 10.1016/j.actbio.2017.10.013] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2017] [Revised: 09/13/2017] [Accepted: 10/09/2017] [Indexed: 02/07/2023]
Abstract
Liver cancer is a globally leading malignancy that has a poor five-year survival rate of less than 20%. The systemic chemotherapeutics are generally ineffective for liver cancers partly due to fast clearance and low tumor uptake. Here, we report that GE11 peptide functionalized polymersomal doxorubicin (GE11-PS-DOX) effectively targets and inhibits epidermal growth factor receptor (EGFR)-positive SMMC7721 orthotopic human liver tumor xenografts in mice. GE11-PS-DOX with a GE11 surface density of 10% displayed a high drug loading of 15.4 wt%, a small size of 78 nm, and glutathione-triggered release of DOX. MTT assays, flow cytometry and confocal microscopy studies revealed that GE11-PS-DOX mediated obviously more efficient DOX delivery into SMMC7721 cells than the non-targeting PS-DOX and clinically used liposomal doxorubicin (Lipo-DOX) controls. The in vivo studies showed that GE11-PS-DOX had a long circulation time and an extraordinary accumulation in the tumors (13.3 %ID/g). Interestingly, GE11-PS-DOX caused much better treatment of SMMC7721 orthotopic liver tumor-bearing mice as compared to PS-DOX and Lipo-DOX. The mice treated with GE11-PS-DOX (12 mg DOX equiv./kg) exhibited a significantly improved survival rate (median survival time: 130 days versus 70 and 38 days for PS-DOX at 12 mg DOX equiv./kg and Lipo-DOX at 6 mg DOX equiv./kg, respectively) and achieved 50% complete regression. Notably, GE11-PS-DOX induced obviously lower systemic toxicity than Lipo-DOX. EGFR-targeted multifunctional polymersomal doxorubicin with improved efficacy and safety has a high potential for treating human liver cancers. STATEMENT OF SIGNIFICANCE Liver cancer is one of the top five leading causes of cancer death worldwide. The systemic chemotherapeutics and biotherapeutics generally have a low treatment efficacy for hepatocellular carcinoma partly due to fast clearance and/or low tumor uptake. Nanomedicines based on biodegradable micelle and polymersomes offer a most promising treatment for malignant liver cancers. Their clinical effectiveness remains, however, suboptimal owing to issues like inadequate systemic stability, low tumor accumulation and selectivity, and poor control over drug release. Here we report that GE11 peptide-functionalized, disulfide-crosslinked multifunctional polymersomal doxorubicin (GE11-PS-DOX) can effectively suppress the growth of orthotopic SMMC7721 human liver tumors in nude mice. They showed significantly decreased systemic toxicity and improved mouse survival rate with 3.4-fold longer median survival time as compared to clinically used pegylated liposomal doxorubicin (Lipo-DOX) and achieving 50% complete regression. GE11-PS-DOX, based on PEG-PTMC is biodegradable, nontoxic, and easy to prepare, appears as a safe, robust, versatile and all-function-in-one nanoplatform that has a high potential in targeted chemotherapy of EGFR expressed hepatocellular carcinoma.
Collapse
|
18
|
Biscaglia F, Rajendran S, Conflitti P, Benna C, Sommaggio R, Litti L, Mocellin S, Bocchinfuso G, Rosato A, Palleschi A, Nitti D, Gobbo M, Meneghetti M. Enhanced EGFR Targeting Activity of Plasmonic Nanostructures with Engineered GE11 Peptide. Adv Healthc Mater 2017; 6. [PMID: 28945012 DOI: 10.1002/adhm.201700596] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Revised: 07/21/2017] [Indexed: 11/11/2022]
Abstract
Plasmonic nanostructures show important properties for biotechnological applications, but they have to be guided on the target for exploiting their potentialities. Antibodies are the natural molecules for targeting. However, their possible adverse immunogenic activity and their cost have suggested finding other valid substitutes. Small molecules like peptides can be an alternative source of targeting agents, even if, as single molecules, their binding affinity is usually not very good. GE11 is a small dodecapeptide with specific binding to the epidermal growth factor receptor (EGFR) and low immunogenicity. The present work shows that thousands of polyethylene glycol (PEG) chains modified with lysines and functionalized with GE11 on clusters of naked gold nanoparticles, obtained by laser ablation in water, achieves a better targeting activity than that recorded with nanoparticles decorated with the specific anti-EGFR antibody Cetuximab (C225). The insertion of the cationic spacer between the polymeric part of the ligand and the targeting peptide allows for a proper presentation of GE11 on the surface of the nanosystems. Surface enhanced resonance Raman scattering signals of the plasmonic gold nanoparticles are used for quantifying the targeting activity. Molecular dynamic calculations suggest that subtle differences in the exposition of the peptide on the PEG sea are important for the targeting activity.
Collapse
Affiliation(s)
- Francesca Biscaglia
- Department of Chemical Sciences; University of Padova; Via Marzolo 1 35131 Padova Italy
| | - Senthilkumar Rajendran
- Department of Surgery Oncology and Gastroenterology; University of Padova; Via Giustiniani, 2 35124 Padova Italy
| | - Paolo Conflitti
- Department of Chemical Sciences & Technologies; University of Roma Tor Vergata and CSGI; Via della Ricerca Scientifica 00133 Rome Italy
| | - Clara Benna
- Department of Surgery Oncology and Gastroenterology; University of Padova; Via Giustiniani, 2 35124 Padova Italy
| | - Roberta Sommaggio
- Department of Surgery Oncology and Gastroenterology; University of Padova; Via Giustiniani, 2 35124 Padova Italy
| | - Lucio Litti
- Department of Chemical Sciences; University of Padova; Via Marzolo 1 35131 Padova Italy
| | - Simone Mocellin
- Department of Surgery Oncology and Gastroenterology; University of Padova; Via Giustiniani, 2 35124 Padova Italy
- Veneto Institute of Oncology IOV-IRCCS; Via Gattamelata, 64 35128 Padova Italy
| | - Gianfranco Bocchinfuso
- Department of Chemical Sciences & Technologies; University of Roma Tor Vergata and CSGI; Via della Ricerca Scientifica 00133 Rome Italy
| | - Antonio Rosato
- Department of Surgery Oncology and Gastroenterology; University of Padova; Via Giustiniani, 2 35124 Padova Italy
- Veneto Institute of Oncology IOV-IRCCS; Via Gattamelata, 64 35128 Padova Italy
| | - Antonio Palleschi
- Department of Chemical Sciences & Technologies; University of Roma Tor Vergata and CSGI; Via della Ricerca Scientifica 00133 Rome Italy
| | - Donato Nitti
- Department of Surgery Oncology and Gastroenterology; University of Padova; Via Giustiniani, 2 35124 Padova Italy
| | - Marina Gobbo
- Department of Chemical Sciences; University of Padova; Via Marzolo 1 35131 Padova Italy
| | - Moreno Meneghetti
- Department of Chemical Sciences; University of Padova; Via Marzolo 1 35131 Padova Italy
| |
Collapse
|
19
|
Wang J, Li Q, Li X, Yuan W, Huang S, Cai S, Xu J. A novel FAPα-based Z-Gly-Pro epirubicin prodrug for improving tumor-targeting chemotherapy. Eur J Pharmacol 2017; 815:166-172. [PMID: 28919026 DOI: 10.1016/j.ejphar.2017.09.016] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Revised: 09/09/2017] [Accepted: 09/12/2017] [Indexed: 01/28/2023]
Abstract
Fibroblast activation protein-α (FAPα) is a serine protease of the post-prolyl peptidase family that is specifically expressed in the majority of human epithelial tumors, but not in normal tissues. In this study, we demonstrated the anti-tumor activity of a novel targeting drug formed by conjugating epirubicin (EPI) with an FAPα-specific dipeptide (Z-Gly-Pro) and named it Z-GP-EPI. Consistent with this tumor-targeting delivery strategy, the results illustrated that Z-GP-EPI could release EPI efficiently after incubating with FAPα and could exhibit similar antitumor effects as EPI in vitro in FAPα over-expressed tumor cells (4T1/FAPα+). Furthermore, the evaluation of antitumor activity of Z-GP-EPI in vivo was implemented in a 4T1/FAPα+ tumor-bearing mice xenograft model. Our results illustrated that Z-GP-EPI had similar antitumor effects in 4T1/FAPα+ tumor-bearing mice and showed no visible cardiotoxicity side effects compared with free EPI. Thus, our study indicated that this FAPα-activated prodrug targeting strategy may provide a new mechanism for the targeted delivery of antitumor agents and improve their safety levels.
Collapse
Affiliation(s)
- Jun Wang
- College of Pharmacy, Jinan University, Guangzhou 510632, PR China
| | - Qiuwen Li
- College of Pharmacy, Jinan University, Guangzhou 510632, PR China
| | - Xiaojuan Li
- College of Pharmacy, Jinan University, Guangzhou 510632, PR China
| | - Weiqi Yuan
- College of Pharmacy, Jinan University, Guangzhou 510632, PR China
| | - Sichao Huang
- College of Pharmacy, Jinan University, Guangzhou 510632, PR China
| | - Shaohui Cai
- College of Pharmacy, Jinan University, Guangzhou 510632, PR China.
| | - Jun Xu
- College of Pharmacy, Jinan University, Guangzhou 510632, PR China.
| |
Collapse
|
20
|
Ding J, Wang K, Tang WJ, Li D, Wei YZ, Lu Y, Li ZH, Liang XF. Construction of Epidermal Growth Factor Receptor Peptide Magnetic Nanovesicles with Lipid Bilayers for Enhanced Capture of Liver Cancer Circulating Tumor Cells. Anal Chem 2016; 88:8997-9003. [PMID: 27558867 DOI: 10.1021/acs.analchem.6b01443] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Highly effective targeted tumor recognition via vectors is crucial for cancer detection. In contrast to antibodies and proteins, peptides are direct targeting ligands with a low molecular weight. In the present study, a peptide magnetic nanovector platform containing a lipid bilayer was designed using a peptide amphiphile (PA) as a skeleton material in a controlled manner without surface modification. Fluorescein isothiocyanate-labeled epidermal growth factor receptor (EGFR) peptide nanoparticles (NPs) could specifically bind to EGFR-positive liver tumor cells. EGFR peptide magnetic vesicles (EPMVs) could efficiently recognize and separate hepatoma carcinoma cells from cell solutions and treated blood samples (ratio of magnetic EPMVs versus anti-EpCAM NPs: 3.5 ± 0.29). Analysis of the circulating tumor cell (CTC) count in blood samples from 32 patients with liver cancer showed that EPMVs could be effectively applied for CTC capture. Thus, this nanoscale, targeted cargo-packaging technology may be useful for designing cancer diagnostic systems.
Collapse
Affiliation(s)
- Jian Ding
- Digestive Department, The First Affiliated Hospital of Fujian Medical University , 20 Chazhong Road, Fuzhou 350005, China
| | - Kai Wang
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine , No.25/Ln2200 Xie Tu Road, Shanghai 200032, China
| | - Wen-Jie Tang
- Research Centre for Translational Medicine, East Hospital, Tongji University School of Medicine , 150 Jimo Road, Shanghai 200120, China
| | - Dan Li
- Digestive Department, Union Hospital of Fujian Medical University , Fuzhou 350001, China
| | - You-Zhen Wei
- Research Centre for Translational Medicine, East Hospital, Tongji University School of Medicine , 150 Jimo Road, Shanghai 200120, China
| | - Ying Lu
- Research Centre for Translational Medicine, East Hospital, Tongji University School of Medicine , 150 Jimo Road, Shanghai 200120, China
| | - Zong-Hai Li
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine , No.25/Ln2200 Xie Tu Road, Shanghai 200032, China
| | - Xiao-Fei Liang
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine , No.25/Ln2200 Xie Tu Road, Shanghai 200032, China
| |
Collapse
|